- Home
- LAAC vs CDXC Comparison
LAAC vs CDXC Comparison
Compare LAAC & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAAC
- CDXC
- Stock Information
- Founded
- LAAC 2007
- CDXC 1999
- Country
- LAAC Canada
- CDXC United States
- Employees
- LAAC N/A
- CDXC N/A
- Industry
- LAAC
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- LAAC
- CDXC Health Care
- Exchange
- LAAC Nasdaq
- CDXC Nasdaq
- Market Cap
- LAAC 490.6M
- CDXC 449.5M
- IPO Year
- LAAC N/A
- CDXC N/A
- Fundamental
- Price
- LAAC $2.77
- CDXC $5.85
- Analyst Decision
- LAAC Buy
- CDXC Strong Buy
- Analyst Count
- LAAC 2
- CDXC 2
- Target Price
- LAAC $5.13
- CDXC $8.00
- AVG Volume (30 Days)
- LAAC 1.1M
- CDXC 346.7K
- Earning Date
- LAAC 03-19-2025
- CDXC 03-05-2025
- Dividend Yield
- LAAC N/A
- CDXC N/A
- EPS Growth
- LAAC 3133.17
- CDXC N/A
- EPS
- LAAC 7.78
- CDXC 0.02
- Revenue
- LAAC N/A
- CDXC $91,668,000.00
- Revenue This Year
- LAAC N/A
- CDXC $18.64
- Revenue Next Year
- LAAC $201.44
- CDXC $20.72
- P/E Ratio
- LAAC $0.35
- CDXC $295.03
- Revenue Growth
- LAAC N/A
- CDXC 9.95
- 52 Week Low
- LAAC $2.07
- CDXC $1.46
- 52 Week High
- LAAC $5.79
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- LAAC 43.19
- CDXC 51.26
- Support Level
- LAAC $2.78
- CDXC $5.60
- Resistance Level
- LAAC $2.89
- CDXC $6.09
- Average True Range (ATR)
- LAAC 0.14
- CDXC 0.27
- MACD
- LAAC -0.01
- CDXC 0.07
- Stochastic Oscillator
- LAAC 18.87
- CDXC 63.30
About LAAC Lithium Americas (Argentina) Corp.
Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.